$ARGX

argenx (ARGX) reported positive Phase 3 trial results for VYVGART Hytrulo in treating autoimmune myositis. Shares have surged, with a 1-year return of 50.58%. Analysts debate valuation, with some calling it 32.2% overvalued at €907.40, while others see a 52.2% discount. Investors should watch for clinical setbacks and pricing pressures.

UBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).

UBS upgraded argenx SE (ARGX) to Buy with a $1,400 price target, citing positive trial results for Vyvgart. ARGX's stock is trading at $1,048.84, 29.0% below its GF Value™ of $1,478.00. The company has a GF Score™ of 78, strong financial health, and a growing pipeline. Institutional interest remains high, with 8 gurus holding shares.

Wells Fargo maintained an Overweight rating on argenx (ARGX) and raised its price target from $1350 to $1415, a 4.81% increase. The company's stock is currently trading at $1019.50, with a GF Value™ of $1478.00, indicating a 31.0% undervaluation. argenx has a GF Score™ of 78/100, reflecting strong financial strength and growth potential. The company focuses on developing antibody-based therapies for rare autoimmune diseases.

argenx (ARGX) reported positive Phase III results for efgartigimod in treating autoimmune myositis, with a 15.4-point improvement in TIS over placebo. The company's shares rose 8% to 789 euros.

UBS upgraded Argenx (ARGX) to Buy with a $1,400 price target, citing Vyvgart's potential for $18B peak sales and a strong pipeline. The stock rose 2.8% in Brussels. Analyst Xian Deng highlighted better-than-expected Phase 3 data and underappreciated pipeline assets, including empasiprubart and a recent $2B acquisition.

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

Argenx (ARGX) reported positive Phase 3 trial results for Vyvgart Hytrulo in treating autoimmune myositis, meeting primary endpoints for IMNM but not DM. The stock surged over 20%. Argenx has multiple late-stage trials and acquisitions in progress, with analysts largely bullish but price targets reflecting modest upside.

UBS upgraded its recommendation for Argenx SE to Buy. The rating is based on a weighted average of several factors, including valuation, EPS revisions, and visibility. The company's shares traded at 897.60 EUR, up 2.09%, on Euronext Bruxelles.

Berenberg downgraded argenx to 'hold' from 'buy' after a 50% rally, citing valuation. The broker raised its price target to €925 from €900 due to positive Vyvgart study results and increased peak sales forecast to $14 billion. Shares rose 1.2% to €874.60.